Biased Dual-Agonists of GLP-1 and Glucagon Receptors Developed Through Conserved Aspartate Mutation
By
W. Michael Seganish
Summary
This article describes a scientific discovery where researchers engineered biased dual-agonists of the glucagon-like peptide 1 receptor (GLP-1R) and glucagon receptor (GCGR) by mutating a conserved aspartate residue. The study explores how targeted mutations can create biased signaling at these receptors, potentially leading to improved therapeutics for metabolic diseases like type 2 diabetes (T2D) that offer better efficacy and reduced side effects compared to existing treatments. The research focuses on understanding the structural and functional mechanisms behind biased agonism at these clinically important receptors.
Source
Twitter / XBiased Dual-Agonists of GLP-1 and Glucagon Receptors Developed Through Conserved Aspartate Mutationgo.acs.orgKey quotes
· 3 pulledDiseases resulting from advanced metabolic syndrome, including type 2 diabetes (T2D), are leading causes of morbidity and a steadily growing health burden.
Agonists of the glucagon-like peptide 1 receptor (GLP-1R) have emerged as a valuable therapy for the treatment of metabolic diseases; they are able to both regulate blood glucose through stimulation of insul
Peptide agonists of the glucagon-like peptide 1 receptor (GLP-1R) have demonstrated clinical efficacy for the management of type 2 diabetes and promote weight loss in addition to glucose-dependent ...
You might also wanna read
Guest Essay: Curiosity-Driven Science Like the Gila Monster Discovery That Led to GLP-1 Drugs Is Under Threat
This guest essay argues that funding for "weird" or curiosity-driven scientific research is under threat, using the example of John Eng's 19
nytimes.com·17d ago
A salute to innovation: exenatide in diabetes and obesity drug development at Amylin Pharmaceuticals - Nature Metabolism
https://www.cell.com/cell/fulltext/S0092-8674(26)00287-4
Semaglutide Shows Chondroprotective Effects in Osteoarthritis Through Weight Loss-Independent Metabolic Mechanism
This research article demonstrates that semaglutide, a GLP-1 receptor agonist, provides chondroprotective effects in osteoarthritis mouse mo
Guest Essay: Serendipitous Gila Monster Venom Research That Led to GLP-1 Drugs Faces Funding Threats
This guest essay argues that funding for "weird" or curiosity-driven scientific research is under threat, using the example of John Eng's 19
nytimes.com·12d ago
Triple hormone drug retatrutide shows promise for diabetes and weight loss in Lancet trial
A new triple hormone drug called retatrutide, which mimics GLP-1, GIP, and glucagon, has shown promising results in a Lancet-published trial
theguardian.com·1mo ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.